Health Care • Biotechnology: Pharmaceutical Preparations
$34.36 ▲ +1.64
(+5.01%)
MKT CAP: $1.60B • VOL: 2.04M
52W L $17 52W H $51
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$29
MEDIAN
$38
MEAN
$39
HIGH
$47
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE URGN TAPE
URGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $41.58 | $39.51 | 2025-02-14 | $31.27 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $43.29 | $40.54 | 2025-02-06 | $32.30 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $39.17 | $37.80 | 2025-01-29 | $32.99 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $35.05 | — | 2025-01-17 | $33.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $30.24 | $32.64 | 2025-01-09 | $30.58 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $40.89 | $35.73 | 2024-12-18 | $29.89 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $33.33 | $34.70 | 2024-12-04 | $31.95 | -4.3% | 48% | C |